Preliminary Q4 2025 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius AG (SUVPF) achieved considerable profitable growth in 2025, with sales revenue increasing by 7.6% in constant currencies.
- The company exceeded its full-year sales guidance and achieved a profitability margin of 29.7%, reflecting strong execution and operational leverage.
- Recurring business across both divisions drove growth, with bioprocess solutions showing strong double-digit growth in recurring revenue.
- Sartorius AG (SUVPF) made significant progress in innovation and partnerships, launching several new solutions and expanding its R&D and production capacity.
- The company reduced its leverage ratio, underscoring its commitment to financial discipline and maintaining a strong balance sheet.
- The non-recurring business remained soft throughout the year, although it showed signs of stabilization in the second half.
- The difference between constant currency and reported growth was negatively impacted by US dollar weakness, representing a headwind of almost 300 basis points.
- Lab products and services division faced challenges, with sales essentially flat and margin declining due to unfavorable product mix and FX impacts.
- The equipment business remained soft, with only stabilization rather than growth, impacting overall performance.
- The company set a broad guidance range for 2026 due to continued macroeconomic and industry-specific volatility, indicating uncertainty in market conditions.
Welcome to the presentation of Sartorius and Sarturiused in Biotext on the preliminary results 2025. Please note that the call is being recorded and streamed on Sartorius's website. Your participation in this implies you consent with this. A replay will be available shortly after the call.
I would now like to turn the conference over to Petra Muller, head of investor relations of Sartorius.
Thank you, operator. Hello and a warm welcome from my side. I'm joined today by our CEO Michel Grosse, by Florian Funk, our CFO, by Rene Faber, head of our bioprocessing division and CEO of the Torres in Biotech, and by Alexandra Gatzenmayer, head of our lab products and services division. As always, we will start with prepared remarks followed by the Q&A session. As the call is scheduled to one hour, please limit your question to one so that as many participants as possible can take part. Please note that management comments during this call will include forward-looking statements that involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
